In a recent study, it was illustrated that the as-needed use in comparison to regular use of Fluticasone Furoate nasal spray in patients with perennial allergic rhinitis had half the drug levels achieved in the body.

The study aimed to explore the as-needed use of intranasal corticosteroid, which is recommended to use regularly for treating perennial allergic rhinitis. 

In this study, there were 103 patients. Fifty-one patients were there in Fluticasone Furoate -as-needed group and fifty-two patients were there in Fluticasone Furoate -regular use group. They were divided to use either fluticasone furoate nasal spray two sprays one time daily for one week, which was followed by as-needed use for five extra weeks or two sprays once every day for six weeks.

The primary result was evaluated using the total nasal symptom score (TNSS). The secondary results were evaluated using nasal peak inspiratory flow (NPIF), cumulative fluticasone furoate dose and Rhinoconjunctivitis Quality of Life-36 Questionnaire Score (RCQ-36).

At week 6, the variation in mean change of TNSS between the two groups was not noteworthy (1.21 points). The Fluticasone Furoate - regular group had a tendency to a greater enhancement in TNSS. The Fluticasone Furoate -regular group, had elevated mean alteration of NPIF than the Fluticasone Furoate -as-needed group at week 6 (-19.21 L/min).

Comparable progress in RCQ-36 was observed in both groups. The mean cumulative Fluticasone Furoate dose in the Fluticasone Furoate -as-needed group was 51 % that of the Fluticasone Furoate -regular group.

Both the groups had comparable progress in TNSS and RCQ-36 in perennial allergic rhinitis. The as-needed group had half of intranasal corticosteroid drug levels achieved in the body as compared to regular use group.